Adjuvant chemo-immunotherapy shows comparable efficacy among mismatch-repair-deficient and mismatch-repair-proficient stage III colon cancer: an exploratory, reconstructed individual patient-level data analysis.

ABSTRACT: The phase III ATOMIC trial recently showed that adding atezolizumab to standard adjuvant chemotherapy improved disease-free survival (DFS) in patients with mismatch-repair-deficient (dMMR) stage III colon cancer; however, its efficacy in mismatch-repair-proficient (pMMR) disease remains unknown. To address this issue, we reconstructed individual patient-level survival data (IPD) for the centrally confirmed dMMR subgroup, as well as those without centrally confirmed dMMR status (an approximation of the pMMR subgroup) in ATOMIC. The analysis of reconstructed IPD faithfully reproduced the trial's reported DFS gain by adding atezolizumab to adjuvant chemotherapy in the dMMR subgroup (3-year DFS, 86.2% vs 77.0%; HR, 0.52 (95% CI 0.36 to 0.77)). Intriguingly, DFS was also in favor of the chemo-i

SUBMITTER: Chen YT 

PROVIDER: S-EPMC12829358 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature